Literature DB >> 32614759

Tumor Treating Fields - behind and beyond inhibiting the cancer cell cycle.

Cédric Kissling1, Stefano Di Santo1.   

Abstract

The unmet need for a safe treatment that significantly improves the overall survival as well as the quality of life of patients with brain tumors has urged researchers to work out new treatment modalities. About 15 years ago it was shown that alternating electric fields significantly impair the growth of cancer cells. Recently, this potentially revolutionary approach called Tumor Treating Fields (TTFs) has been FDA-approved for treatment of glioblastoma as well as mesothelioma. However, despite the promising reports on the potential of TTFs the precise knowledge of the mechanisms of action is still lacking. The purpose of this review is thus to present the current state of research and to highlight the variety of ultrastructural effects of TTFs. Moreover, we aim to bring to the foreground less discussed mechanisms of action of TTFs which might develop into novel therapeutic approaches. Therefore, a systematic literature search in Ovid Medline and Embase was performed on clinical and preclinical data concerning TTFs. The alternating electric fields force cellular components to aberrant dynamics among which the most evident is the inhibition of the mitotic spindle assembly leading in impaired cancer cell division and cell death. However, a variety of other microstructural events induced by TTFs such as an inhibition of DNA repair and cell migration as well as an enhancement of anti-tumor immune response and membrane permeability have been reported. In addition, apart from a suggested interference with angiogenesis, no TTF-induced effects on normal cells have been described so far. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Brain Neoplasms; Cancer Treatment; Cell Cycle; Central Nervous System; TTF; Tumor Treating Fields

Year:  2020        PMID: 32614759     DOI: 10.2174/1871527319666200702144749

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  4 in total

1.  A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors.

Authors:  Hui Fang; Shuyan Sheng; Bangjie Chen; Jianpeng Wang; Deshen Mao; Yanxun Han; Yuchen Liu; Xinyi Wang; Siyu Gui; Tongyuan Zhang; Lizhi Zhang; Conghan Li; Xinyang Hu; Wanyu Deng; Xin Liu; Honghai Xu; Wentao Xu; Xingyu Wang; Rongqiang Liu; Weihao Kong
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 2.  Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.

Authors:  Xiaopeng Guo; Xin Yang; Jiaming Wu; Huiyu Yang; Yilin Li; Junlin Li; Qianshu Liu; Chen Wu; Hao Xing; Penghao Liu; Yu Wang; Chunhua Hu; Wenbin Ma
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

3.  CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma.

Authors:  Yuanyuan Bai; Shangfan Liao; Zhenjie Yin; Bingyong You; Dongming Lu; Yongmei Chen; Daoxun Chen; Yongyang Wu
Journal:  J Oncol       Date:  2022-09-28       Impact factor: 4.501

4.  Development of health-based exposure limits for radiofrequency radiation from wireless devices using a benchmark dose approach.

Authors:  Uloma Igara Uche; Olga V Naidenko
Journal:  Environ Health       Date:  2021-07-17       Impact factor: 5.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.